Abnormal T2-STIR magnetic resonance in hypertrophic cardiomyopathy: a marker of advanced disease and electrical myocardial instability

PLoS One. 2014 Oct 30;9(10):e111366. doi: 10.1371/journal.pone.0111366. eCollection 2014.

Abstract

Background: Myocardial hyperintensity on T2-weighted short-tau inversion recovery (STIR) (HyT2) cardiac magnetic resonance (CMR) images has been demonstrated in patients with hypertrophic cardiomyopathy (HCM) and is considered a sign of acute damage. The aim of the current study was to evaluate the relationship between HyT2 and both a) markers of ventricular electrical instability and b) clinical and CMR parameters.

Methods: Sixty-five patients underwent a thorough clinical examination, consisting of 24-h ECG recording and CMR examination including functional evaluation, T2-STIR images and late gadolinium enhancement (LGE).

Results: HyT2 was detected in 27 patients (42%), and subjects with HyT2 showed a greater left ventricle (LV) mass index (p<0.001), lower LV ejection fraction (p = 0.05) and greater extent of LGE (p<0.001) compared to those without HyT2. Twenty-two subjects (34%) presented non-sustained ventricular tachycardia (NSVT) on the 24-h ECG recording, 21 (95%) of whom exhibited HyT2. Based on the logistic regression analysis, HyT2 (odds ratio [OR]: 165, 95% CI 11-2455, p<0.001) and LGE extent (1.1, 1.0-1.3, p<0.001) served as independent predictors of NSVT, while the presence of LGE was not associated with NSVT occurrence (p = 0.49). The presence of HyT2 was associated with lower heart rate variability (p = 0.006) and a higher number of arrhythmic risk factors (p<0.001).

Conclusions: In HCM patients, HyT2 upon CMR examination is associated with more advanced disease and increased arrhythmic burden.

MeSH terms

  • Biomarkers
  • Cardiomyopathy, Hypertrophic / pathology*
  • Cardiomyopathy, Hypertrophic / physiopathology*
  • Electrophysiological Phenomena*
  • Female
  • Humans
  • Magnetic Resonance Spectroscopy*
  • Male
  • Middle Aged
  • Myocardium / pathology*
  • Tachycardia, Ventricular / physiopathology

Substances

  • Biomarkers

Grants and funding

The authors received no specific funding for this work.